The Road to Recovery,    We are open.    We are clean.    We are ready.   Learn More!
School of Nursing | HNH Fitness | Villa Marie Claire | Simulation Learning | About Holy Name | Careers | Ways to Give

We are open.
We are clean.
We are ready.

Holy Name Medical Center is happy to announce that we have begun our return to normal operations. You may wonder, Is the hospital safe? Yes. We are ready. Ready to partner with you and your family on all your healthcare needs.

Holy Name is the first hospital in North Jersey to complete a rigorous, deep cleaning of our 450,000 square feet of clinical and non-clinical space. We started with manual disinfection, then applied electrostatic sanitizing mist, and finally, blasted UV-C light to kill more than 30 types of pathogens — including Covid-19.

Learn How Holy Name Became COVID-19 Clean

Now is a good time to think about your overall health and wellness. How can Holy Name help you?

View our services A-Z

Medical Care


Patients & Visitors




About Holy Name Medical Center About Holy Name Medical Center

Key Phone Numbers

  • Medical Center Operator

  • 201-833-3000

  • Physician Referral Service

  • 877-HOLY-NAME (465-9626)

  • Patient Information

  • 201-833-3300

  • Foundation (Donations)

  • 201-833-3187

  • Human Resources

  • 201-833-7040

  • Medical Staff Office

  • 201-833-3352

View All Department Contact Numbers

For general questions or comments, email info@holyname.org


For More Information:

201-541-5900
201-541-6305

Types of Breast Cancer

There are many different types of breast cancer and treatment options may differ depending on the type and stage of the cancer.

  • Ductal carcinoma in situ (DCIS) - A non-invasive breast cancer limited to inside the duct of the breast, meaning it hasn't spread, and is classified as Stage 0. It has no symptoms and is usually spotted on a mammogram.

  • HER2 - A growth-promoting protein located on the outside of breast cells. Tumors with higher levels of HER2 tend to grow and spread faster than other types of breast cancers.

  • Hormone Receptor Positive - When cancer cells grow in response (receptor positive) to the hormones estrogen or progesterone.

  • Inflammatory breast cancer (IBC) - This type of breast cancer is rare, aggressive and fast-growing. Cancer cells block lymph vessels in the breast, causing a buildup of fluid (lymph) in the breast skin. The breast will often look swollen, red, purple or bruised. The skin may also have ridges or appear pitted, like an orange peel. The disease typically develops quickly and may not create a tumor that can be felt. Immediate care is recommended. If an infection or rash on the breast does not clear up after treatment with antibiotics or topical remedies, prompt follow-up care is advised.

  • Invasive ductal carcinoma (IDC) - This is the most common type of breast cancer. It begins growing in the milk duct and then invades the surrounding tissue. A lump or mass may be found during a breast self-exam or there may be no symptoms. A mammogram may also reveal a suspicious mass, which requires further testing.

  • Invasive lobular carcinoma (ILC) - Although this is the second most common type of breast cancer, it still accounts for only about 10 percent of all cases. It starts in the milk-producing lobules of the breast and invades the surrounding tissue. It may produce no symptoms, be discovered as a palpable mass during a self-exam, or as a density in a mammogram.

  • Metastatic breast cancer - A diagnosis of metastatic breast cancer means the cancer has spread to other organs in the body.

  • Paget's disease of the breast - This rare form of breast cancer causes a skin change in the areola or nipple. Signs include nipple or areola redness, an eczema-like rash, a break in the skin or crusting. Nipple discharge or inversion may also occur. It typically affects women in their 50s but can appear at younger or older ages.

  • Triple Negative - The name of this type of breast cancer refers to its characteristics, estrogen-receptor negative, progesterone-receptor negative and HER2-receptor negative. This means targeted therapies that attack specific genes or proteins on cancer cells are not effective, though it typically responds to chemotherapy. Between 10 and 15 percent of breast cancer patients have triple negative, a particularly aggressive form of the disease.